CN101972238A - Prescription of phenazopyridine hydrochloride capsule and preparation process - Google Patents
Prescription of phenazopyridine hydrochloride capsule and preparation process Download PDFInfo
- Publication number
- CN101972238A CN101972238A CN 201010514206 CN201010514206A CN101972238A CN 101972238 A CN101972238 A CN 101972238A CN 201010514206 CN201010514206 CN 201010514206 CN 201010514206 A CN201010514206 A CN 201010514206A CN 101972238 A CN101972238 A CN 101972238A
- Authority
- CN
- China
- Prior art keywords
- phenazopyridine hydrochloride
- capsule
- preparation process
- prescription
- easy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a prescription of a phenazopyridine hydrochloride capsule and a preparation process thereof, belonging to the technical field of medicament preparations. The capsule is prepared by mixing phenazopyridine hydrochloride used as a raw material with a proper amount of auxiliary materials. The material phenazopyridine hydrochloride is colored and is easy to cause pollution, the color is easy to seep out of a coating after a film coat is coated, even PVP (Polyvinylpyrrolidone) seeps out of some capsules, and qualified products are difficult to produce. The capsule is prepared by rationally proportioning the phenazopyridine hydrochloride and the auxiliary materials, has simple preparation process, is easy to control, has stable product quality, solves the problem of color seepage and is convenient to produce.
Description
Technical field
The invention belongs to technical field of medicine, relate to capsular prescription of a kind of phenazopyridine hydrochloride and preparation technology.
Background technology
Phenazopyridine hydrochloride is a kind of urethra local analgesia medicine, directly acts on mucous membrane of urethra, is used to alleviate urethra and bladder pain and discomfort due to cystitis, prostatitis and the urethritis, burning sensation, frequent micturition, urgent micturition etc.The side effect of no cholinolytic medicine, and can be used with antibiotic.Go through an edition American Pharmacopeia (USP) and repeatedly record this medicine, up-to-date American Pharmacopeia also records the raw material and the tablet of this medicine, to the world wide penetration and promotion.In multinational listings such as Canada, France, Britain, Japan, Switzerland, Germany, Belgium, Spain, Holland, South Africa, use lasting clinically.Its reason just is that this product has unique pharmacological action and safety, is mucous membrane of urethra local analgesia medicine unique in the global marketed drug.Abroad in treatment first-selected sulfa drugs and phenazopyridine drug combination as therapeutic scheme, but when treating urinary tract infection at home, the anti-mattress extract for treating of in most cases simple use, at this section of antibiotic control infection in the period, patient's symptom can not be controlled effectively, therefore the misery that adds the heavy patient undoubtedly, and the domestic whole body analgesic of can only using need a kind of mucous membrane of urethra, local anesthesia, symptomatolytic medicine of directly acting on.This shows that phenazopyridine hydrochloride has enormous and latent market at home.
But because the phenazopyridine hydrochloride raw material itself has color, be easy to pollute, the tablet of external import is the bag Film coated tablets.But domestic a lot of enterprise finds that in when research color was easy to ooze out coating after the bag film-coat was placed a period of time, in addition have ooze out PVP, therefore, the research of this product and produce and bring very big puzzlement to enterprise.
Summary of the invention
The present invention is directed to the problem that the Baridium color is exosmosed, adopt rational ratio of adjuvant, the phenazopyridine hydrochloride capsule of making through study on the stability research, constant product quality, has overcome the color problem of exosmosing.
For achieving the above object, technical scheme of the present invention is as follows:
The present invention is that adjuvant comprises one or more in lubricant, diluent, the disintegrating agent by phenazopyridine hydrochloride and the encapsulated capsule of making of auxiliary materials and mixing.Lubricant is one or more in magnesium stearate, Pulvis Talci, Polyethylene Glycol, the micropowder silica gel; Diluent is one or more in dextrin, microcrystalline Cellulose, the Icing Sugar; Disintegrating agent is one or more in starch, carboxymethyl starch sodium, the crospolyvinylpyrrolidone.
The best proportioning of medicine and adjuvant is 1: 1--1: 2, and the best prescription proportioning:
Form content (percentage by weight)
Medicine 30%--50%
Lubricant 40%--60%
Diluent 1%--5%
Disintegrating agent 1%--5%
The specific embodiment
With the following Examples the present invention is done detailed elaboration, but be not limited to the embodiment of these concrete records.
Embodiment 1:
The capsular preparation method of a kind of phenazopyridine hydrochloride, preparation process is as follows:
Form umber (weight meter)
1 part of medicine
0.25 part of Pulvis Talci
0.03 part of magnesium stearate
0.38 part of microcrystalline Cellulose
0.12 part of Icing Sugar
0.22 part of starch
Take by weighing the supplementary material of above-mentioned prescription proportioning, after the pulverizing, put mixing in the vortex mixer, directly the encapsulating capsule promptly.
Embodiment 2:
The capsular preparation method of a kind of phenazopyridine hydrochloride, preparation process is as follows:
Form umber (weight meter)
1 part of medicine
0.55 part of Pulvis Talci
0.08 part of magnesium stearate
0.71 part of microcrystalline Cellulose
0.22 part of Icing Sugar
0.44 part of starch
Take by weighing the supplementary material of above-mentioned prescription proportioning, after the pulverizing, put mixing in the vortex mixer, directly the encapsulating capsule promptly.
Claims (3)
1. phenazopyridine hydrochloride capsule is characterized in that by phenazopyridine hydrochloride and the capsule that is mixed and made into according to a certain ratio of acceptable adjuvant medically.
2. according to claim 1, the best proportioning that it is characterized in that supplementary material is 1: 1-1: 2.
3. according to claim 1, above-mentioned adjuvant comprises lubricant, diluent and disintegrating agent, and lubricant is one or more in magnesium stearate, Pulvis Talci, Polyethylene Glycol, the micropowder silica gel; Diluent is one or more in dextrin, microcrystalline Cellulose, the Icing Sugar; Disintegrating agent is one or more in starch, carboxymethyl starch sodium, the crospolyvinylpyrrolidone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010514206 CN101972238A (en) | 2010-10-21 | 2010-10-21 | Prescription of phenazopyridine hydrochloride capsule and preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010514206 CN101972238A (en) | 2010-10-21 | 2010-10-21 | Prescription of phenazopyridine hydrochloride capsule and preparation process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101972238A true CN101972238A (en) | 2011-02-16 |
Family
ID=43572170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010514206 Pending CN101972238A (en) | 2010-10-21 | 2010-10-21 | Prescription of phenazopyridine hydrochloride capsule and preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101972238A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102311383A (en) * | 2011-10-12 | 2012-01-11 | 山东罗欣药业股份有限公司 | Phenazopyridine hydrochloride crystal compound and pharmaceutical composition tablet thereof |
| CN108635335A (en) * | 2018-06-13 | 2018-10-12 | 刘兆平 | A kind of phenazopyridine hydrochloride capsule and preparation process |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051356A1 (en) * | 2003-10-31 | 2005-06-09 | Elan Pharma International Ltd. | Novel nimesulide compositions |
-
2010
- 2010-10-21 CN CN 201010514206 patent/CN101972238A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005051356A1 (en) * | 2003-10-31 | 2005-06-09 | Elan Pharma International Ltd. | Novel nimesulide compositions |
Non-Patent Citations (1)
| Title |
|---|
| 《中国临床药学杂志》 20061231 彭文兴等 盐酸非那吡啶在中国健康志愿者体内的生物等效性 第289-292页 1-3 第15卷, 第5期 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102311383A (en) * | 2011-10-12 | 2012-01-11 | 山东罗欣药业股份有限公司 | Phenazopyridine hydrochloride crystal compound and pharmaceutical composition tablet thereof |
| CN108635335A (en) * | 2018-06-13 | 2018-10-12 | 刘兆平 | A kind of phenazopyridine hydrochloride capsule and preparation process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101822673B (en) | Iloperidone-containing solid medicinal composition | |
| CN101011464A (en) | Composite propolis soft capsule | |
| CN104352471A (en) | Fluvoxamine maleate sustained release tablets and preparation method thereof | |
| CN102160855B (en) | Dex-ibuprofen sustained release tablets and preparation method thereof | |
| CN101972238A (en) | Prescription of phenazopyridine hydrochloride capsule and preparation process | |
| CN109453169B (en) | Application of bulleyaconitine A | |
| CN105560207B (en) | A kind of aurantiin controlled release capsule and preparation method thereof | |
| CN102283927A (en) | Technology for preparing novel integrated dosage form of windflower decoction | |
| CN102283928A (en) | Technology for preparing novel integrated dosage form of Ermiao powder and production method thereof | |
| CN103356630B (en) | Containing pentoxifylline and the pharmaceutical composition of prucalopride and medical usage thereof | |
| CN101474258B (en) | Ficus microcarpa var.pusillifolia extract, extracting method and application of the extract | |
| CN101352440B (en) | Guaifenesin, pseudoephedrine hydrochloride and dextromethorphan hydrobromide sustained-release preparation and preparation method thereof | |
| CN104367562A (en) | Pramipexole dihydrochloride slow-release tablets and preparation method thereof | |
| CN101721380A (en) | Method for preparing sustained-release preparation | |
| CN101518519A (en) | Naringin slow-release tablet and method for preparing same | |
| CN108635335A (en) | A kind of phenazopyridine hydrochloride capsule and preparation process | |
| CN104188930B (en) | Acemetacin three-layer controlled release tablets and preparation method thereof | |
| CN102188405A (en) | New cavity administration preparation formulation | |
| CN102100897A (en) | Preparation technology and preparation method of novel integrative Erchen decoction dosage form | |
| CN102225065B (en) | Parcetamol pseudoephedrine hydrochloride and dextromethorphan hydrochloride capsule and preparation method thereof | |
| CN101732357A (en) | Chinese medicinal powder for treating pediatric archocele | |
| CN102283936A (en) | Integrated novel form preparation technology for Sisheng Wan and production method thereof | |
| CN100551369C (en) | A kind of slow releasing preparation that contains cilostazol and preparation method thereof | |
| CN102100890A (en) | Preparation technology of new integrative formulation of cassia twig decoction and production method thereof | |
| CN103655644A (en) | Aescine oral preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20110216 |